Integrated filing (financials) for the Quarter and Year ended March 31st 2025.

Revenue growth above 20%Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.5%Reaction day

₹28.57

prior close

₹27.96

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-5.4% vs market

Pharmaceuticals peers, median of 146sector-0.2%-5.3% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.5-0.1-5.4-0.2-5.3

Next day

-1.6+4.5-6.2+2.5-4.1

-5.6+6.2-11.8+4.0-9.5

-10.2+7.9-18.1+4.4-14.6

-5.7+9.0-14.7+5.1-10.8

-2.1+9.9-11.9+5.5-7.5

-6.9+10.0-16.9+5.5-12.4

15d

-12.1+13.1-25.2+7.3-19.5

-15.2+15.5-30.7+7.9-23.0

-19.7+16.8-36.5+8.9-28.6

+2.3+11.3-9.0+3.1-0.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 146Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venmax Drugs posted total revenue of Rs. 186.05 lakhs in FY25 versus Rs. 19.86 lakhs in FY24, driven mainly by other income of Rs. 105.32 lakhs; revenue from operations was Rs. 80.73 lakhs (vs nil in FY24). The company slipped into a small loss of Rs. 1.05 lakhs in FY25 compared to a profit of Rs. 6.45 lakhs in FY24, with Q4 alone showing a profit of Rs. 77.82 lakhs. The balance sheet ballooned to Rs. 516.96 lakhs (from Rs. 8.14 lakhs) after the company received Rs. 507.25 lakhs as 25% upfront money for 1 crore convertible warrants issued on a preferential basis. Cash on hand jumped to Rs. 248.24 lakhs, while accumulated losses stood at Rs. 589.95 lakhs. The statutory auditor (PPKG & Co.) issued an unmodified (clean) audit opinion, and the company confirmed no loan defaults and no related party transactions.

Likely market impact

The clean audit opinion and fresh capital infusion from the warrant issue are positives, but persistent accumulated losses, a negative operating cash flow of Rs. 229 lakhs, and negligible operating revenue suggest the company is still in turnaround mode and dependent on non-core income and fresh capital for survival.